기업 정보 불러오는 중
Keep exploring
The themes Palatin Technologies is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.US$47.6BA+
EXELExelixis, Inc.US$16.8BA+
JAZZJazz Pharmaceuticals plcUS$15.5BA
TECHBIO-Techne CorpUS$11.4BA+
HALOHalozyme Therapeutics, Inc.US$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026년 10월 21일CBGraded C, now B
MCKMckesson Corporation2026년 11월 4일BAGraded B, now A
CVSCVS Health Corp2026년 11월 4일BAGraded B, now A
EWEdwards Lifesciences Corporation2026년 11월 4일BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026년 10월 28일CAGraded C, now A
어떻게 돈을 버는가
- Licensing and research collaborations
경쟁 상대
무엇을 파는가4
Next-generation long-acting MC4R peptide agonist
An experimental peptide medicine being developed as a once-weekly injection for obesity, with a focus on rare conditions involving appetite and weight regulation.
Next-generation oral MC4R small-molecule agonist
An experimental medicine taken by mouth that Palatin is preparing for further development for rare obesity disorders.
PL9643
An experimental peptide medicine for dry eye disease. Palatin licensed development and commercialization rights to Altanispac Labs.
PL8177
An experimental oral peptide medicine studied for inflammatory bowel diseases, including ulcerative colitis; Palatin is seeking a development partner.
누가 사는가2
- Pharmaceutical companies that license drug candidates or development rights and may pay upfront fees, research funding, milestone payments and royalties.
- Biopharmaceutical partners, including Boehringer Ingelheim and Altanispac Labs, which take responsibility for developing or commercializing licensed programs.
무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가
사업이 기대고 있는 것
- 1Needs additional funding to carry out research and clinical development; management has identified substantial doubt about its ability to continue as a going concern.
- 2Relies on partners such as Boehringer Ingelheim and Altanispac Labs to advance licensed medicines; payments beyond initial fees depend on future development, regulatory and sales milestones.
- 3Relies on outside manufacturers, suppliers and research organizations for drug materials, manufacturing and studies.
잘못될 수 있는 일
- 1Palatin may be unable to raise the money needed to continue operations and develop its drug candidates.
- 2Its main internally funded obesity candidates are at an early stage, and clinical studies or regulatory review may fail to support their use as medicines.
- 3Partner-led programs may not advance or produce milestone payments and royalties if collaborators do not develop or commercialize the medicines successfully.
Palatin Technologies Inc. 소개
Palatin's main in-house work targets the melanocortin 4 receptor (MC4R), which is involved in appetite and body weight, with injectable and oral drug candidates for rare obesity disorders. It also develops or licenses medicines aimed at inflammatory diseases, including eye and bowel conditions. Its former approved drug Vyleesi was acquired by Cosette in 2023; Palatin now seeks income from licensing, research funding, milestone payments and, if licensed medicines reach the market, royalties.
- 본사
- Princeton, New Jersey, United States
- 설립
- 1986 (incorporated; biopharmaceutical operations began in 1996)
- 임직원 수
- 25 (September 25, 2026, high)
- 상장 시장
- Nasdaq Capital Market
- 회계연도 종료
- June 30
Palatin Technologies Inc.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.
